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Feline panleukopenia virus (FPV) is a single-stranded 
DNA virus of the family Parvoviridae and the genus 
Parvovirus. All members of Felidae and cats of all ages 
can be infected.1,2 Owing to high morbidity and high 
mortality of the infection, the FPV vaccine is considered a 
core vaccine, and current guidelines on vaccination rec-
ommend vaccinating as often as necessary, but not more 
than necessary. Experts recommend vaccinating kittens 
every 3–4 weeks up to 16 weeks of age followed by a 
booster vaccination after 1 year and further vaccinations 
on a triennial basis.3–6 In a population in which the virus 
is still endemic, many cats are likely to have antibodies 
and be protected either because of exposure or vaccina-
tion. As the presence of antibodies is considered to indi-
cate protection from disease, antibody testing can be used 
to determine protection or susceptibility of individual 
cats. Furthermore, it can be used to evaluate the immune 
response after vaccination and the efficacy of vaccines in 
experimental settings.7–10 Titre testing to determine 
whether a cat has specific antibodies against FPV is a use-
ful tool in individualised medicine. However, it has so far 
not been established in Germany. Its major aim in small 
animal practice is to determine whether a cat is poten-
tially unprotected against FPV and requires FPV vaccina-
tion. Thus, using titre testing instead of just vaccinating a 
potentially protected cat can prevent over-vaccination in 
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Abstract
Measuring antibody titres to determine a cat’s immunity to core diseases instead of just administering annual 
vaccinations has not been established in Germany so far. An in-house test kit for the detection of antibodies against 
feline panleukopenia virus (FPV), feline herpesvirus-1 and feline calicivirus – the ImmunoComb Feline VacciCheck – 
is now available in several European countries. The aim of this study was to assess the quality of the ImmunoComb 
Feline VacciCheck to determine antibodies by comparing it to a gold standard. The test is aimed for use in practice 
to assist decision-making when performing an individual health assessment to see whether a cat is potentially 
unprotected against FPV and requires FPV vaccination. Sera from 347 cats were included in the study. For antibody 
detection, haemagglutination inhibition (HI) was performed as gold standard. Sensitivity, specificity and positive 
and negative predictive values of the ImmunoComb Feline VacciCheck were determined for three different HI titre 
cut-off points (1:20, 1:40, 1:80). In comparison to the HI, the ImmunoComb Feline VacciCheck showed a sensitivity 
of 79%, 83% and 87%, and a specificity of 89%, 86% and 81%, respectively. Specificity of the ImmunoComb Feline 
VacciCheck, which was considered the most important parameter, was acceptable in comparison to HI. Especially 
when considering an antibody titre of 1:20 sufficient for protection (eg, in an adult animal), the ImmunoComb Feline 
VacciCheck can be recommended for use in veterinary practice.
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the adult cat population. Haemagglutination inhibition 
(HI) is considered to be the gold standard of measuring 
antibodies against FPV,8,11,12 but the HI titre cut-off point 
to predict protection is still debated, and different studies 
consider different HI titre cut-off points as protective.8,13,14 
While titre determination by HI in a commercial labora-
tory is time-consuming, an in-house test that provides 
rapid and reliable results would be useful in everyday 
practice. Very recently, an in-house test arrived on the 
German market. The test detects antibodies against FPV, 
feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV) 
(ImmunoComb Feline VacciCheck; Biogal). One study 
investigated the performance of this test in detecting FPV 
antibodies in young, presumed unvaccinated cats enter-
ing a shelter in Florida, USA.14 Since then, the test has 
been modified in an aim to increase sensitivity. So far, no 
study has evaluated this modified antibody in-house test 
in a diverse population of cats in Europe that included 
cats of different origin, source area, environment, hous-
ing conditions, and health and vaccination status.
Thus, the aims of this study were to evaluate the 
ImmunoComb Feline VacciCheck in the field by compar-
ing the FPV results to those of the HI (gold standard) 
using different HI titre cut-off points (1:20, 1:40, 1:80) by 
measuring sensitivity, specificity, and positive (PPVs) 
and negative predictive values (NPVs), and furthermore 
to evaluate the practicability of the test. FHV-1 and FCV 
results were not evaluated.
Materials and methods
Cats
The study was designed as a prospective cross-sectional 
study. All cats (n = 347) that were presented from 
December 2011 to June 2012 to the Clinic of Small Animal 
Medicine and to the Clinic of Small Animal Surgery and 
Gynaecology of the Ludwig-Maximilians-University of 
Munich, Germany, and that needed a blood sample for 
preventive health assessment or for diagnostic purposes 
in sick animals, were included in the study. Blood was 
collected by venepuncture of the vena cephalica antebra-
chii, vena saphena, or vena jugularis. For data collection, 
medical records were studied and missing data were col-
lected via a structured telephone interview. Cats were 
excluded if there were no historical data available (ie, in 
stray cats). The study protocol was approved by the 
ethics committee of the Centre for Veterinary Clinical 
Medicine, Ludwig-Maximilians-University of Munich, 
Germany (licence number 3-5-10-2012).
ImmunoComb Feline VacciCheck
After blood sampling, sera were directly separated by 
centrifugation and stored at −20°C until processed. All 
samples were analysed with the ImmunoComb Feline 
VacciCheck according to manufacturer’s instructions. 
Each antibody test kit contained a comb-shaped plastic 
card and a multi-compartment developing plate for test-
ing 12 sera in parallel (Figure 1). The manufacturer 
declares that the positive control of the test would be 
equivalent to an antibody titre of 1:80 in HI. The test is 
based on an enzyme-linked immunosorbent assay prin-
ciple and detects antibodies against FPV, FHV-1 and 
FCV (FHV-1 and FCV results were not part of this study). 
After stepwise washing and binding of an enzyme-
linked anti-cat immunoglobulin G antibody, a grey col-
our tone developed in the last step. A colour tone equal 
to or darker than the positive control was regarded as a 
positive result; a colour tone paler than the positive con-
trol was regarded as a negative result.
HI
All samples were analysed by the gold standard HI. HI 
is a laboratory test to measure antibodies against FPV. As 
FPV agglutinates swine erythrocytes, antibodies present 
in the sample prevent attachment of the virus to these 
erythrocytes and therefore inhibit haemagglutination. 
Samples underwent heat inactivation (56°C for 30 mins), 
were diluted with borate buffered saline (BBS) 1:5 and 
then pre-adsorbed to 15 µl of a 50% suspension of swine 
erythrocytes in phosphate buffered saline (PBS) for 1 h at 
4°C. After centrifugation for 5 mins, the supernatant was 
subsequently two-fold diluted serially over 12 steps 
beginning at 1:10 in 96-well V-bottomed plates (Greiner 
Bio-One). Eight haemagglutinating units of FPV-b (strain 
292, as used and described in previous studies15,16) in 
BBS were added to each well and incubated for 1 h at 
room temperature. Then, a 0.5% suspension of swine 
erythrocytes in PBS was added and incubated at 4°C 
Figure 1 ImmunoComb Feline VacciCheck antibody test 
kit containing a comb-shaped plastic card and a multi-
compartment developing plate
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overnight. The reciprocal of the highest dilution of serum 
that inhibited haemagglutination was defined as the HI 
titre of the serum. Different antibody titres were used as 
HI titre cut-off points for a positive result (1:20, 1:40, 
1:80).
Statistical analysis
For test evaluation, the following performance parame-
ters were calculated using a 2 × 2 contingency table: sen-
sitivity, specificity, PPV and NPV. To quantify uncertainty, 
95% confidence intervals (CIs) were calculated. The 
prevalence (and 95% CI) was calculated as the propor-
tion of positive results of the total number of tested sera. 
Performance parameters and prevalences were calcu-
lated for three different HI titre cut-off points (1:20, 1:40, 
1:80). Statistical analysis was performed using commer-
cial software (SPSS).
For evaluation of the diagnostic performance specific-
ity was set as the most important parameter. As a prede-
fined criterion, a specificity of ⩾90% was considered a 
good performance, a specificity of 80–90% was set as 
acceptable, and a specificity of <80% was considered as 
unacceptable for recommendation of the test.
Results
Study population
Cats in the study were of a variety of breeds, female 
(n = 149) or male (n = 198), neutered (n = 306) or sexually 
intact (n = 41). The median age was 9 years and ranged 
from 6 weeks to 20 years. Cats came from private house-
holds (n = 140), animal shelters (n = 41), breeders 
(n = 30), foreign countries (n = 59) or were formerly stray 
cats (n = 30) (origin). Cats lived in either urban (n = 298) 
or rural communities (n = 49) (source area) and were 
kept indoors (n = 194) or outdoors (n = 133) (environ-
ment), as a single cat (n = 138) or in multi-cat households 
(n = 187) (housing conditions). At the time of presenta-
tion, cats were healthy (n = 33), or acutely (n = 127) or 
chronically ill (n = 187) (health status). Most cats had a 
history of prior vaccination (n = 282). Twenty-eight cats 
had never been vaccinated.
Sensitivity, specificity and predictive values
The results of all sera tested with the ImmunoComb 
Feline VacciCheck compared to HI are shown in 
Table 1. For the three different HI titre cut-off points 
(1:20, 1:40, 1:80), the test showed 9, 14 and 23 false- 
positive results, respectively. Specificities of the 
ImmunoComb Feline VacciCheck were 89%, 86% and 
81%, respectively (Table 2).
Prevalence
Prevalence of antibodies against FPV, when considering 
a HI titre cut-off point of 1:20, 1:40 or 1:80 as positive, 
was 77% (267/347), 71% (245/347) and 65% (225/347), 
respectively (Table 2). Antibody prevalence measured by 
the ImmunoComb Feline VacciCheck was 63% (218/347; 
95% CI 58–68).
Practicability of the ImmunoComb Feline 
VacciCheck
All 347 sera showed valid results in the ImmunoComb 
Feline VacciCheck and could clearly be classified as posi-
tive or negative. Twelve sera could be processed in paral-
lel. The test always delivered results in 21 mins, as 
described in the manufacturer’s instruction manual.
Discussion
FPV is a frequent disease that occurs in young and old 
cats.2 In a retrospective study that investigated prognostic 
factors for survival of cats with panleukopenia, 244 cats 
that were presented to the Clinic of Small Animal 
Medicine, Ludwig-Maximilians-University of Munich, 
Germany, were diagnosed with FPV between 1990 and 
2007.2 According to current guidelines, ideally, all cats 
should be protected against FPV infection at any time, if 
not through immunity following natural infection, then 
by vaccination.3–6 Although rare in cats, mild-to-severe 
adverse events after vaccination occur; these include 
feline injection-site sarcomas (FISS) that often recur after 
surgery and have a guarded prognosis.17–19 FISS occur 
more commonly after adjuvanted inactivated vaccines,19 
but have also been described after vaccination against 
FPV, FHV-1 and FCV.20 As immunological protection 
against FPV is long-lived,21 vaccination should ideally 
only be performed in animals that are unprotected.
In adult vaccinated cats, regardless of vaccine type or 
vaccination interval, or cats that overcame infection, 
detection of FPV-specific antibodies is predictive of pro-
tection. Thus, measurement of antibodies against FPV 
can be used to assess the immune status in these cats.8,9,21 
A fast and reliable in-house test would be an excellent 
tool for veterinarians to perform modern individualised 
medicine and avoid over-vaccination.
Table 1 Results of all 347 sera in the ImmunoComb Feline 
VacciCheck compared to haemagglutination inhibition (HI) 































Total 129 218 347
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The intended use of the test evaluated in this study is 
to assess the specific immune status of cats by detecting 
antibodies, either before or after regular vaccinations in 
veterinary practice. When evaluating a test, samples 
should be representative for the intended use of the 
test.22 Thus, a diverse population of cats that mimics the 
actual population in a small animal practice regarding 
signalment, origin, source area, environment, housing 
conditions, and health and vaccination status was cho-
sen in the present study. However, this clinic population 
cannot be assumed to be representative for the national 
cat population.
In this study, 347 sera were analysed. Prevalence of 
antibodies against FPV was 77%, 71% and 65%, depend-
ing on the chosen HI titre cut-off point. Similar FPV anti-
body prevalences were described in 267 client-owned 
cats in the USA (67%).8 A remarkably lower antibody 
prevalence was found in cats entering a Florida (USA) 
animal shelter (40%). In that study, 67% of the cats enter-
ing the shelter were stray cats. In these cats, a low vacci-
nation rate is the most reasonable explanation for the 
low antibody prevalence at the time of blood sampling. 
In addition, differences in environmental exposure to 
FPV can be a reason for the different prevalences.
For the detection of antibodies against FPV, HI served 
as the gold standard in this study.8,11,12 The method is 
very specific for the virus, and the technique is simple 
and well established. In addition, equipment and rea-
gents are quite inexpensive. However, this test cannot be 
performed in practice. Another limitation of the method 
is that reading the plate is subjective, which could lead to 
false-positive or false-negative results. However, to min-
imise subjective evaluation, HI plates were read by two 
independent people: one was the first author (KM) and 
one was an experienced laboratory technician. Divergent 
results were checked by a second laboratory technician.
Specificity was set as the most important parameter in 
this study. For use in the context of an individual health 
assessment and as a tool for deciding whether a cat 
needs vaccination, it is essential to obtain a low number 
of false-positive test results, so that potentially unpro-
tected cats can be identified.
The manufacturer of the ImmunoComb Feline 
VacciCheck declares a HI titre cut-off point of ⩾1:80 as a 
positive result. However, when considering a HI titre 
cut-off point of 1:80 as a positive result, the specificity of 
the ImmunoComb Feline VacciCheck in this study 
would only be 81%. There was a relatively high number 
(23) of false-positive test results. The PPV was still rela-
tively high (89%), which, however, is influenced by the 
high antibody prevalence in this study. According to the 
predefined criterion, the specificity of the test was not 
good when basing the result on a HI titre cut-off point of 
1:80. This specificity would be remarkably lower than 
those described previously for the ImmunoComb Feline 
VacciCheck, for example, in the shelter study in Florida, 
USA (99%),14 and in the manufacturer’s product infor-
mation (98%). On the contrary, the sensitivity of the test 
(87%) was higher than in the shelter study in Florida 
(49%),14 but not as good as declared by the manufacturer 
(90%). In this study, 30 sera tested false-negative. False-
negative results, however, are not as problematic as 
false-positive results. Cats with false-negative test results 
will receive a booster vaccination even if they are pro-
tected against infection at the time of blood sampling. 
The difference between test results in the shelter study 
and the present study, as well as the declaration by the 
manufacturer concerning sensitivity and specificity, 
could be due to recent modifications to the test by the 
manufacturer.
It is still debated which antibody titre is equivalent to 
protection in adult cats. In former studies, even lower 
(<1:80) antibody titres were considered to be predictive 
for protection against FPV infection in cats that were for-
merly vaccinated or who had overcome infection.13,23 In 
one study, cats were considered to be protected against 
infection with FPV if they had a titre of ⩾1:40 in HI 
before vaccination.13 Considering a HI titre cut-off point 
of 1:40 as protective, the specificity of the ImmunoComb 
Feline VacciCheck in this study would be 86%.
Table 2 Performance parameters of the ImmunoComb Feline VacciCheck based on results given in Table 1: sensitivity, 
specificity, and positive (PPV) and negative predictive value (NPV) (and 95% confidence interval [CI]), calculated using 
haemagglutination inhibition (HI) at three different HI titre cut-off points (1:20, 1:40, 1:80) as gold standard
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At present, however, the presence of antibodies even 
at a low concentration (such as titres of 1:20) is consid-
ered protective in cats that have been vaccinated after 
maternally derived antibodies have dropped, or in cats 
that have overcome infection, as these indicate a response 
of the immune system to an antigen.8,24,25 In challenge 
experiments, the presence of antibody titres of 1:20 in 
previously vaccinated cats was predictive for protection 
against disease.8 When basing the results of the present 
study on a HI titre cut-off point of 1:20, specificity of the 
ImmunoComb Feline VacciCheck was 89% and thus 
almost reached the predefined criterion for a good test 
performance. Based on this HI titre cut-off point, the test 
showed a low number (nine) of false-positive results, 
which is important in helping to decide whether a cat 
requires FPV vaccination.
The test has some benefits concerning the practicabil-
ity compared with titre testing at a laboratory. As the test 
can be performed in about 21 mins, results are available 
during consultation and can be used immediately for 
decision-making. Furthermore, up to 12 samples can be 
processed in parallel. Another advantage is the low 
amount of blood required. The test just requires 5 µl of 
serum or plasma, or 10 µl of whole blood, whereas for HI 
only serum can be used and at least 100 µl is needed.
As FHV-1 and FCV results were not evaluated in this 
study, no recommendation can be given about the test’s 
usefulness in determining FHV-1 and FCV antibodies in 
the field of small animal practice.
One limitation of the study is that the amount of anti-
bodies indicating protection is still unclear. A true pro-
tection can only be determined by challenge experiments, 
which, of course, was not possible in this study with pri-
vately owned cats.
Conclusions
The ImmunoComb Feline VacciCheck showed a high 
specificity for the detection of antibodies against FPV. 
When considering an antibody titre of 1:20 in HI to be 
protective, the test almost reached the predefined crite-
rion of 90% (89%) for a good performance and at least 
delivered acceptable results. Thus, the test can be rec-
ommended for use in veterinary practice to help in 
deciding whether a cat requires FPV vaccination. 
However, further modification by the manufacturer, 
aiming for an even higher specificity of the test, would 
be desirable to reduce the risk of missing and not vac-
cinating unprotected cats.
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